Phreesia, Inc. (PHR) Stock Competitors & Peer Comparison
See (PHR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PHR | $10.11 | -2.41% | 596.2M | 60.28 | $0.16 | N/A |
| BTSGU | $193.55 | -0.64% | 39B | N/A | N/A | N/A |
| VEEV | $179.37 | -1.95% | 29.1B | 32.87 | $5.43 | N/A |
| GEHC | $64.28 | +3.69% | 28.2B | 14.88 | $4.17 | +0.23% |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | N/A |
| BTSG | $59.10 | -0.40% | 11.8B | 79.06 | $0.77 | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| TEM | $52.52 | +5.84% | 8.3B | -27.62 | -$1.72 | N/A |
| HQY | $88.29 | -0.06% | 7.1B | 31.91 | $2.67 | N/A |
| RCM | $14.31 | N/A | 6B | -102.21 | -$0.14 | N/A |
Stock Comparison
PHR vs BTSGU Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, BTSGU has a market cap of 39B. Regarding current trading prices, PHR is priced at $10.11, while BTSGU trades at $193.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas BTSGU's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to BTSGU's ROE of +0.13%. Regarding short-term risk, PHR is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check BTSGU's competition here
PHR vs VEEV Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, VEEV has a market cap of 29.1B. Regarding current trading prices, PHR is priced at $10.11, while VEEV trades at $179.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas VEEV's P/E ratio is 32.87. In terms of profitability, PHR's ROE is +0.03%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, PHR is less volatile compared to VEEV. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check VEEV's competition here
PHR vs GEHC Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, GEHC has a market cap of 28.2B. Regarding current trading prices, PHR is priced at $10.11, while GEHC trades at $64.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas GEHC's P/E ratio is 14.88. In terms of profitability, PHR's ROE is +0.03%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, PHR is more volatile compared to GEHC. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check GEHC's competition here
PHR vs GEHCV Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, PHR is priced at $10.11, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas GEHCV's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, PHR is less volatile compared to GEHCV. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check GEHCV's competition here
PHR vs BTSG Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, BTSG has a market cap of 11.8B. Regarding current trading prices, PHR is priced at $10.11, while BTSG trades at $59.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas BTSG's P/E ratio is 79.06. In terms of profitability, PHR's ROE is +0.03%, compared to BTSG's ROE of +0.13%. Regarding short-term risk, PHR is more volatile compared to BTSG. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check BTSG's competition here
PHR vs SGFY Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, PHR is priced at $10.11, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas SGFY's P/E ratio is 70.91. In terms of profitability, PHR's ROE is +0.03%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, PHR is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check SGFY's competition here
PHR vs TEM Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, TEM has a market cap of 8.3B. Regarding current trading prices, PHR is priced at $10.11, while TEM trades at $52.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas TEM's P/E ratio is -27.62. In terms of profitability, PHR's ROE is +0.03%, compared to TEM's ROE of -0.70%. Regarding short-term risk, PHR is less volatile compared to TEM. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check TEM's competition here
PHR vs HQY Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, HQY has a market cap of 7.1B. Regarding current trading prices, PHR is priced at $10.11, while HQY trades at $88.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas HQY's P/E ratio is 31.91. In terms of profitability, PHR's ROE is +0.03%, compared to HQY's ROE of +0.11%. Regarding short-term risk, PHR is more volatile compared to HQY. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check HQY's competition here
PHR vs RCM Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, PHR is priced at $10.11, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas RCM's P/E ratio is -102.21. In terms of profitability, PHR's ROE is +0.03%, compared to RCM's ROE of +0.00%. Regarding short-term risk, PHR is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check RCM's competition here
PHR vs HNGE Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, HNGE has a market cap of 4.5B. Regarding current trading prices, PHR is priced at $10.11, while HNGE trades at $62.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas HNGE's P/E ratio is -6.59. In terms of profitability, PHR's ROE is +0.03%, compared to HNGE's ROE of -1.39%. Regarding short-term risk, PHR is less volatile compared to HNGE. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check HNGE's competition here
PHR vs TXG Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, TXG has a market cap of 4.1B. Regarding current trading prices, PHR is priced at $10.11, while TXG trades at $35.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas TXG's P/E ratio is -189.18. In terms of profitability, PHR's ROE is +0.03%, compared to TXG's ROE of -0.03%. Regarding short-term risk, PHR is less volatile compared to TXG. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check TXG's competition here
PHR vs DOCS Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, DOCS has a market cap of 3.9B. Regarding current trading prices, PHR is priced at $10.11, while DOCS trades at $21.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas DOCS's P/E ratio is 21.47. In terms of profitability, PHR's ROE is +0.03%, compared to DOCS's ROE of +0.19%. Regarding short-term risk, PHR is more volatile compared to DOCS. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check DOCS's competition here
PHR vs ONEM Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, PHR is priced at $10.11, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas ONEM's P/E ratio is -7.77. In terms of profitability, PHR's ROE is +0.03%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, PHR is more volatile compared to ONEM. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check ONEM's competition here
PHR vs PRVA Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, PRVA has a market cap of 2.6B. Regarding current trading prices, PHR is priced at $10.11, while PRVA trades at $21.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas PRVA's P/E ratio is 121.53. In terms of profitability, PHR's ROE is +0.03%, compared to PRVA's ROE of +0.03%. Regarding short-term risk, PHR is more volatile compared to PRVA. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check PRVA's competition here
PHR vs HTFL Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, HTFL has a market cap of 2.5B. Regarding current trading prices, PHR is priced at $10.11, while HTFL trades at $30.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas HTFL's P/E ratio is -9.34. In terms of profitability, PHR's ROE is +0.03%, compared to HTFL's ROE of +8.30%. Regarding short-term risk, PHR is less volatile compared to HTFL. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check HTFL's competition here
PHR vs PINC Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, PINC has a market cap of 2.3B. Regarding current trading prices, PHR is priced at $10.11, while PINC trades at $28.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas PINC's P/E ratio is 166.24. In terms of profitability, PHR's ROE is +0.03%, compared to PINC's ROE of -0.02%. Regarding short-term risk, PHR is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check PINC's competition here
PHR vs PGNY Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, PGNY has a market cap of 2B. Regarding current trading prices, PHR is priced at $10.11, while PGNY trades at $25.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas PGNY's P/E ratio is 32.46. In terms of profitability, PHR's ROE is +0.03%, compared to PGNY's ROE of +0.13%. Regarding short-term risk, PHR is more volatile compared to PGNY. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check PGNY's competition here
PHR vs OMCL Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, OMCL has a market cap of 1.9B. Regarding current trading prices, PHR is priced at $10.11, while OMCL trades at $44.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas OMCL's P/E ratio is 95.20. In terms of profitability, PHR's ROE is +0.03%, compared to OMCL's ROE of +0.02%. Regarding short-term risk, PHR is more volatile compared to OMCL. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check OMCL's competition here
PHR vs NXGN Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, PHR is priced at $10.11, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas NXGN's P/E ratio is -266.00. In terms of profitability, PHR's ROE is +0.03%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, PHR is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check NXGN's competition here
PHR vs WGS Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, WGS has a market cap of 1.6B. Regarding current trading prices, PHR is priced at $10.11, while WGS trades at $55.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas WGS's P/E ratio is -19.93. In terms of profitability, PHR's ROE is +0.03%, compared to WGS's ROE of -0.28%. Regarding short-term risk, PHR is less volatile compared to WGS. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check WGS's competition here
PHR vs AGTI Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, PHR is priced at $10.11, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas AGTI's P/E ratio is -71.79. In terms of profitability, PHR's ROE is +0.03%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, PHR is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check AGTI's competition here
PHR vs TDOC Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, TDOC has a market cap of 1.3B. Regarding current trading prices, PHR is priced at $10.11, while TDOC trades at $7.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas TDOC's P/E ratio is -7.30. In terms of profitability, PHR's ROE is +0.03%, compared to TDOC's ROE of -0.12%. Regarding short-term risk, PHR is less volatile compared to TDOC. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check TDOC's competition here
PHR vs SDGR Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, SDGR has a market cap of 1.1B. Regarding current trading prices, PHR is priced at $10.11, while SDGR trades at $16.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas SDGR's P/E ratio is -10.66. In terms of profitability, PHR's ROE is +0.03%, compared to SDGR's ROE of -0.31%. Regarding short-term risk, PHR is less volatile compared to SDGR. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check SDGR's competition here
PHR vs OMDA Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, OMDA has a market cap of 1B. Regarding current trading prices, PHR is priced at $10.11, while OMDA trades at $18.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas OMDA's P/E ratio is -75.35. In terms of profitability, PHR's ROE is +0.03%, compared to OMDA's ROE of -0.03%. Regarding short-term risk, PHR is less volatile compared to OMDA. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check OMDA's competition here
PHR vs GDRX Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, GDRX has a market cap of 974M. Regarding current trading prices, PHR is priced at $10.11, while GDRX trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas GDRX's P/E ratio is 46.83. In terms of profitability, PHR's ROE is +0.03%, compared to GDRX's ROE of +0.03%. Regarding short-term risk, PHR is less volatile compared to GDRX. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check GDRX's competition here
PHR vs CERT Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, CERT has a market cap of 871.2M. Regarding current trading prices, PHR is priced at $10.11, while CERT trades at $5.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas CERT's P/E ratio is -56.00. In terms of profitability, PHR's ROE is +0.03%, compared to CERT's ROE of -0.01%. Regarding short-term risk, PHR is less volatile compared to CERT. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check CERT's competition here
PHR vs CCLDO Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, PHR is priced at $10.11, while CCLDO trades at $27.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas CCLDO's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, PHR is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check CCLDO's competition here
PHR vs NUTX Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, NUTX has a market cap of 790.9M. Regarding current trading prices, PHR is priced at $10.11, while NUTX trades at $137.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas NUTX's P/E ratio is 9.72. In terms of profitability, PHR's ROE is +0.03%, compared to NUTX's ROE of +0.31%. Regarding short-term risk, PHR is less volatile compared to NUTX. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check NUTX's competition here
PHR vs HSTM Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, HSTM has a market cap of 716.9M. Regarding current trading prices, PHR is priced at $10.11, while HSTM trades at $25.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas HSTM's P/E ratio is 36.63. In terms of profitability, PHR's ROE is +0.03%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, PHR is more volatile compared to HSTM. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check HSTM's competition here
PHR vs MPLN-WT Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, PHR is priced at $10.11, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to MPLN-WT's ROE of +2.06%. Regarding short-term risk, PHR is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check MPLN-WT's competition here
PHR vs ACCD Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, PHR is priced at $10.11, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas ACCD's P/E ratio is -3.08. In terms of profitability, PHR's ROE is +0.03%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, PHR is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check ACCD's competition here
PHR vs SHCR Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, PHR is priced at $10.11, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas SHCR's P/E ratio is -3.76. In terms of profitability, PHR's ROE is +0.03%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, PHR is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check SHCR's competition here
PHR vs CTEV Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, CTEV has a market cap of 448.4M. Regarding current trading prices, PHR is priced at $10.11, while CTEV trades at $27.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas CTEV's P/E ratio is -1.52. In terms of profitability, PHR's ROE is +0.03%, compared to CTEV's ROE of +2.06%. Regarding short-term risk, PHR is less volatile compared to CTEV. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check CTEV's competition here
PHR vs NRC Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, NRC has a market cap of 429.1M. Regarding current trading prices, PHR is priced at $10.11, while NRC trades at $19.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas NRC's P/E ratio is 45.33. In terms of profitability, PHR's ROE is +0.03%, compared to NRC's ROE of +0.57%. Regarding short-term risk, PHR is more volatile compared to NRC. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check NRC's competition here
PHR vs EVH Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, EVH has a market cap of 424.6M. Regarding current trading prices, PHR is priced at $10.11, while EVH trades at $4.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas EVH's P/E ratio is -0.81. In terms of profitability, PHR's ROE is +0.03%, compared to EVH's ROE of -0.78%. Regarding short-term risk, PHR is less volatile compared to EVH. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check EVH's competition here
PHR vs SLGC Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, PHR is priced at $10.11, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas SLGC's P/E ratio is -3.04. In terms of profitability, PHR's ROE is +0.03%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, PHR is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check SLGC's competition here
PHR vs SLGCW Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, PHR is priced at $10.11, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, PHR's ROE is +0.03%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, PHR is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check SLGCW's competition here
PHR vs TBRG Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, TBRG has a market cap of 389.5M. Regarding current trading prices, PHR is priced at $10.11, while TBRG trades at $26.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas TBRG's P/E ratio is 89.55. In terms of profitability, PHR's ROE is +0.03%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, PHR is more volatile compared to TBRG. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check TBRG's competition here
PHR vs MPLN Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, PHR is priced at $10.11, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas MPLN's P/E ratio is -0.23. In terms of profitability, PHR's ROE is +0.03%, compared to MPLN's ROE of +2.06%. Regarding short-term risk, PHR is less volatile compared to MPLN. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check MPLN's competition here
PHR vs SOPH Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, SOPH has a market cap of 342.6M. Regarding current trading prices, PHR is priced at $10.11, while SOPH trades at $4.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas SOPH's P/E ratio is -4.05. In terms of profitability, PHR's ROE is +0.03%, compared to SOPH's ROE of -1.41%. Regarding short-term risk, PHR is less volatile compared to SOPH. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check SOPH's competition here
PHR vs SLP Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, SLP has a market cap of 326.7M. Regarding current trading prices, PHR is priced at $10.11, while SLP trades at $16.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas SLP's P/E ratio is -5.18. In terms of profitability, PHR's ROE is +0.03%, compared to SLP's ROE of -0.49%. Regarding short-term risk, PHR is more volatile compared to SLP. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check SLP's competition here
PHR vs TRHC Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, PHR is priced at $10.11, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas TRHC's P/E ratio is -4.27. In terms of profitability, PHR's ROE is +0.03%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, PHR is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check TRHC's competition here
PHR vs CARL Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, CARL has a market cap of 277.3M. Regarding current trading prices, PHR is priced at $10.11, while CARL trades at $11.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas CARL's P/E ratio is -10.41. In terms of profitability, PHR's ROE is +0.03%, compared to CARL's ROE of -0.62%. Regarding short-term risk, PHR is less volatile compared to CARL. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check CARL's competition here
PHR vs SY Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, SY has a market cap of 255.9M. Regarding current trading prices, PHR is priced at $10.11, while SY trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas SY's P/E ratio is -5.13. In terms of profitability, PHR's ROE is +0.03%, compared to SY's ROE of -0.16%. Regarding short-term risk, PHR is more volatile compared to SY. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check SY's competition here
PHR vs SMFR Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, PHR is priced at $10.11, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas SMFR's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to SMFR's ROE of -0.28%. Regarding short-term risk, PHR is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check SMFR's competition here
PHR vs SPOK Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, SPOK has a market cap of 221.2M. Regarding current trading prices, PHR is priced at $10.11, while SPOK trades at $10.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas SPOK's P/E ratio is 17.95. In terms of profitability, PHR's ROE is +0.03%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, PHR is more volatile compared to SPOK. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check SPOK's competition here
PHR vs AMWL Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, AMWL has a market cap of 140.5M. Regarding current trading prices, PHR is priced at $10.11, while AMWL trades at $8.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas AMWL's P/E ratio is -1.55. In terms of profitability, PHR's ROE is +0.03%, compared to AMWL's ROE of -0.35%. Regarding short-term risk, PHR is more volatile compared to AMWL. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check AMWL's competition here
PHR vs CPSI Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, PHR is priced at $10.11, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas CPSI's P/E ratio is -183.80. In terms of profitability, PHR's ROE is +0.03%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, PHR is less volatile compared to CPSI. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check CPSI's competition here
PHR vs AUGX Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, PHR is priced at $10.11, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas AUGX's P/E ratio is -4.99. In terms of profitability, PHR's ROE is +0.03%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, PHR is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check AUGX's competition here
PHR vs CCLD Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, CCLD has a market cap of 99.9M. Regarding current trading prices, PHR is priced at $10.11, while CCLD trades at $2.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas CCLD's P/E ratio is 18.08. In terms of profitability, PHR's ROE is +0.03%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, PHR is more volatile compared to CCLD. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check CCLD's competition here
PHR vs HCAT Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, HCAT has a market cap of 98.3M. Regarding current trading prices, PHR is priced at $10.11, while HCAT trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas HCAT's P/E ratio is -0.36. In terms of profitability, PHR's ROE is +0.03%, compared to HCAT's ROE of -1.00%. Regarding short-term risk, PHR is less volatile compared to HCAT. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check HCAT's competition here
PHR vs OPRX Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, OPRX has a market cap of 92.9M. Regarding current trading prices, PHR is priced at $10.11, while OPRX trades at $5.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas OPRX's P/E ratio is 13.75. In terms of profitability, PHR's ROE is +0.03%, compared to OPRX's ROE of +0.05%. Regarding short-term risk, PHR is less volatile compared to OPRX. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check OPRX's competition here
PHR vs DH Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, DH has a market cap of 92.6M. Regarding current trading prices, PHR is priced at $10.11, while DH trades at $0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas DH's P/E ratio is -0.53. In terms of profitability, PHR's ROE is +0.03%, compared to DH's ROE of -0.67%. Regarding short-term risk, PHR is more volatile compared to DH. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check DH's competition here
PHR vs FORA Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, FORA has a market cap of 67.8M. Regarding current trading prices, PHR is priced at $10.11, while FORA trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas FORA's P/E ratio is -24.11. In terms of profitability, PHR's ROE is +0.03%, compared to FORA's ROE of -0.17%. Regarding short-term risk, PHR is more volatile compared to FORA. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check FORA's competition here
PHR vs CCLDP Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, PHR is priced at $10.11, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas CCLDP's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, PHR is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check CCLDP's competition here
PHR vs ONMD Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, ONMD has a market cap of 41.7M. Regarding current trading prices, PHR is priced at $10.11, while ONMD trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas ONMD's P/E ratio is -19.16. In terms of profitability, PHR's ROE is +0.03%, compared to ONMD's ROE of +0.90%. Regarding short-term risk, PHR is more volatile compared to ONMD. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check ONMD's competition here
PHR vs SNCE Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, PHR is priced at $10.11, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas SNCE's P/E ratio is -0.27. In terms of profitability, PHR's ROE is +0.03%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, PHR is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check SNCE's competition here
PHR vs AKLI Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, PHR is priced at $10.11, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas AKLI's P/E ratio is -0.71. In terms of profitability, PHR's ROE is +0.03%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, PHR is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check AKLI's competition here
PHR vs SHLT Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, PHR is priced at $10.11, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas SHLT's P/E ratio is -3.87. In terms of profitability, PHR's ROE is +0.03%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, PHR is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check SHLT's competition here
PHR vs SHCRW Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, PHR is priced at $10.11, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, PHR's ROE is +0.03%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, PHR is more volatile compared to SHCRW. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check SHCRW's competition here
PHR vs EUDA Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, EUDA has a market cap of 31.1M. Regarding current trading prices, PHR is priced at $10.11, while EUDA trades at $16.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas EUDA's P/E ratio is -11.24. In terms of profitability, PHR's ROE is +0.03%, compared to EUDA's ROE of +0.13%. Regarding short-term risk, PHR is less volatile compared to EUDA. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check EUDA's competition here
PHR vs BEAT Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, BEAT has a market cap of 30.7M. Regarding current trading prices, PHR is priced at $10.11, while BEAT trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas BEAT's P/E ratio is -1.59. In terms of profitability, PHR's ROE is +0.03%, compared to BEAT's ROE of -10.34%. Regarding short-term risk, PHR is less volatile compared to BEAT. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check BEAT's competition here
PHR vs ONMDW Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, ONMDW has a market cap of 30.4M. Regarding current trading prices, PHR is priced at $10.11, while ONMDW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas ONMDW's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to ONMDW's ROE of +0.90%. Regarding short-term risk, PHR is more volatile compared to ONMDW. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check ONMDW's competition here
PHR vs STRM Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, PHR is priced at $10.11, while STRM trades at $5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas STRM's P/E ratio is -2.40. In terms of profitability, PHR's ROE is +0.03%, compared to STRM's ROE of -0.32%. Regarding short-term risk, PHR is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check STRM's competition here
PHR vs RNLX Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, PHR is priced at $10.11, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas RNLX's P/E ratio is -0.33. In terms of profitability, PHR's ROE is +0.03%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, PHR is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check RNLX's competition here
PHR vs LIFW Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, PHR is priced at $10.11, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas LIFW's P/E ratio is -0.02. In terms of profitability, PHR's ROE is +0.03%, compared to LIFW's ROE of +3.93%. Regarding short-term risk, PHR is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check LIFW's competition here
PHR vs BBLN Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, PHR is priced at $10.11, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas BBLN's P/E ratio is -0.04. In terms of profitability, PHR's ROE is +0.03%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, PHR is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check BBLN's competition here
PHR vs ETAO Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, PHR is priced at $10.11, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas ETAO's P/E ratio is -0.01. In terms of profitability, PHR's ROE is +0.03%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, PHR is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check ETAO's competition here
PHR vs BFRG Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, BFRG has a market cap of 7.7M. Regarding current trading prices, PHR is priced at $10.11, while BFRG trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas BFRG's P/E ratio is -1.35. In terms of profitability, PHR's ROE is +0.03%, compared to BFRG's ROE of -2.18%. Regarding short-term risk, PHR is more volatile compared to BFRG. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check BFRG's competition here
PHR vs HLTH Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, PHR is priced at $10.11, while HLTH trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas HLTH's P/E ratio is -0.02. In terms of profitability, PHR's ROE is +0.03%, compared to HLTH's ROE of -0.90%. Regarding short-term risk, PHR is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check HLTH's competition here
PHR vs SCNX Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, SCNX has a market cap of 5.7M. Regarding current trading prices, PHR is priced at $10.11, while SCNX trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas SCNX's P/E ratio is -0.15. In terms of profitability, PHR's ROE is +0.03%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, PHR is more volatile compared to SCNX. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check SCNX's competition here
PHR vs UPH-WT Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, PHR is priced at $10.11, while UPH-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, PHR is less volatile compared to UPH-WT. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check UPH-WT's competition here
PHR vs UPH Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, PHR is priced at $10.11, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas UPH's P/E ratio is -0.07. In terms of profitability, PHR's ROE is +0.03%, compared to UPH's ROE of -1.05%. Regarding short-term risk, PHR is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check UPH's competition here
PHR vs PEARW Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, PHR is priced at $10.11, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas PEARW's P/E ratio is -0.00. In terms of profitability, PHR's ROE is +0.03%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, PHR is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check PEARW's competition here
PHR vs PEAR Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, PHR is priced at $10.11, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas PEAR's P/E ratio is -0.08. In terms of profitability, PHR's ROE is +0.03%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, PHR is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check PEAR's competition here
PHR vs MGRX Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, MGRX has a market cap of 3.8M. Regarding current trading prices, PHR is priced at $10.11, while MGRX trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas MGRX's P/E ratio is -0.30. In terms of profitability, PHR's ROE is +0.03%, compared to MGRX's ROE of -1.21%. Regarding short-term risk, PHR is less volatile compared to MGRX. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check MGRX's competition here
PHR vs HCTI Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, HCTI has a market cap of 2.7M. Regarding current trading prices, PHR is priced at $10.11, while HCTI trades at $2.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas HCTI's P/E ratio is 0.01. In terms of profitability, PHR's ROE is +0.03%, compared to HCTI's ROE of -0.68%. Regarding short-term risk, PHR is less volatile compared to HCTI. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check HCTI's competition here
PHR vs BEATW Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, BEATW has a market cap of 2.7M. Regarding current trading prices, PHR is priced at $10.11, while BEATW trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas BEATW's P/E ratio is -0.16. In terms of profitability, PHR's ROE is +0.03%, compared to BEATW's ROE of -10.34%. Regarding short-term risk, PHR is less volatile compared to BEATW. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check BEATW's competition here
PHR vs VSEE Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, VSEE has a market cap of 2.6M. Regarding current trading prices, PHR is priced at $10.11, while VSEE trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas VSEE's P/E ratio is -0.30. In terms of profitability, PHR's ROE is +0.03%, compared to VSEE's ROE of -115.71%. Regarding short-term risk, PHR is more volatile compared to VSEE. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check VSEE's competition here
PHR vs OTRK Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, PHR is priced at $10.11, while OTRK trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas OTRK's P/E ratio is -0.02. In terms of profitability, PHR's ROE is +0.03%, compared to OTRK's ROE of -1.66%. Regarding short-term risk, PHR is more volatile compared to OTRK. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check OTRK's competition here
PHR vs BFRGW Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, BFRGW has a market cap of 2.2M. Regarding current trading prices, PHR is priced at $10.11, while BFRGW trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas BFRGW's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to BFRGW's ROE of -2.18%. Regarding short-term risk, PHR is less volatile compared to BFRGW. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check BFRGW's competition here
PHR vs ACON Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, ACON has a market cap of 1.9M. Regarding current trading prices, PHR is priced at $10.11, while ACON trades at $3.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas ACON's P/E ratio is -0.62. In terms of profitability, PHR's ROE is +0.03%, compared to ACON's ROE of -0.54%. Regarding short-term risk, PHR is more volatile compared to ACON. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check ACON's competition here
PHR vs CMAX Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, PHR is priced at $10.11, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas CMAX's P/E ratio is -0.00. In terms of profitability, PHR's ROE is +0.03%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, PHR is more volatile compared to CMAX. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check CMAX's competition here
PHR vs LIFWZ Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, PHR is priced at $10.11, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to LIFWZ's ROE of +3.93%. Regarding short-term risk, PHR is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check LIFWZ's competition here
PHR vs VSEEW Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, VSEEW has a market cap of 1M. Regarding current trading prices, PHR is priced at $10.11, while VSEEW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas VSEEW's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to VSEEW's ROE of -115.71%. Regarding short-term risk, PHR is less volatile compared to VSEEW. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check VSEEW's competition here
PHR vs EUDAW Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, EUDAW has a market cap of 990.6K. Regarding current trading prices, PHR is priced at $10.11, while EUDAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas EUDAW's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to EUDAW's ROE of +0.13%. Regarding short-term risk, PHR is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check EUDAW's competition here
PHR vs MSPRZ Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, PHR is priced at $10.11, while MSPRZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to MSPRZ's ROE of +3.93%. Regarding short-term risk, PHR is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check MSPRZ's competition here
PHR vs MSPR Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, MSPR has a market cap of 370.5K. Regarding current trading prices, PHR is priced at $10.11, while MSPR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas MSPR's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to MSPR's ROE of +3.93%. Regarding short-term risk, PHR is less volatile compared to MSPR. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check MSPR's competition here
PHR vs WORX Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, WORX has a market cap of 303.5K. Regarding current trading prices, PHR is priced at $10.11, while WORX trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas WORX's P/E ratio is -0.20. In terms of profitability, PHR's ROE is +0.03%, compared to WORX's ROE of -0.65%. Regarding short-term risk, PHR is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check WORX's competition here
PHR vs ZCMD Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, ZCMD has a market cap of 173.8K. Regarding current trading prices, PHR is priced at $10.11, while ZCMD trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas ZCMD's P/E ratio is -0.03. In terms of profitability, PHR's ROE is +0.03%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, PHR is less volatile compared to ZCMD. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check ZCMD's competition here
PHR vs WGSWW Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, WGSWW has a market cap of 170.7K. Regarding current trading prices, PHR is priced at $10.11, while WGSWW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas WGSWW's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to WGSWW's ROE of -0.28%. Regarding short-term risk, PHR is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check WGSWW's competition here
PHR vs KERN Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, PHR is priced at $10.11, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas KERN's P/E ratio is -0.01. In terms of profitability, PHR's ROE is +0.03%, compared to KERN's ROE of -0.17%. Regarding short-term risk, PHR is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check KERN's competition here
PHR vs KERNW Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, PHR is priced at $10.11, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas KERNW's P/E ratio is -0.00. In terms of profitability, PHR's ROE is +0.03%, compared to KERNW's ROE of -0.17%. Regarding short-term risk, PHR is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check KERNW's competition here
PHR vs LIFWW Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, PHR is priced at $10.11, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas LIFWW's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to LIFWW's ROE of +3.93%. Regarding short-term risk, PHR is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check LIFWW's competition here
PHR vs OTRKP Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, OTRKP has a market cap of 50.1K. Regarding current trading prices, PHR is priced at $10.11, while OTRKP trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas OTRKP's P/E ratio is -0.00. In terms of profitability, PHR's ROE is +0.03%, compared to OTRKP's ROE of -1.66%. Regarding short-term risk, PHR is less volatile compared to OTRKP. This indicates potentially lower risk in terms of short-term price fluctuations for PHR.Check OTRKP's competition here
PHR vs CMAXW Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, PHR is priced at $10.11, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas CMAXW's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, PHR is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check CMAXW's competition here
PHR vs ACONW Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, ACONW has a market cap of 15.7K. Regarding current trading prices, PHR is priced at $10.11, while ACONW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas ACONW's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to ACONW's ROE of -0.54%. Regarding short-term risk, PHR is more volatile compared to ACONW. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check ACONW's competition here
PHR vs ICCT Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, ICCT has a market cap of 5.4K. Regarding current trading prices, PHR is priced at $10.11, while ICCT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas ICCT's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to ICCT's ROE of +11.65%. Regarding short-term risk, PHR is more volatile compared to ICCT. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check ICCT's competition here
PHR vs FOXO Comparison June 2026
PHR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHR stands at 596.2M. In comparison, FOXO has a market cap of 3K. Regarding current trading prices, PHR is priced at $10.11, while FOXO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHR currently has a P/E ratio of 60.28, whereas FOXO's P/E ratio is N/A. In terms of profitability, PHR's ROE is +0.03%, compared to FOXO's ROE of -0.97%. Regarding short-term risk, PHR is more volatile compared to FOXO. This indicates potentially higher risk in terms of short-term price fluctuations for PHR.Check FOXO's competition here